

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UPDATED INFORMATION ON THE GROUP'S PRODUCT INSULIN DEGLUDEC INJECTION**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 12 October 2024, the application for marketing of Insulin Degludec Injection (specifications: 3ml: 300U (refilled pen-type); 3ml: 300U (disposable pen-type)) submitted by Zhuhai United Bio-Pharmaceutical Co., Ltd, a wholly-owned subsidiary of the Company, has been accepted by China National Medical Products Administration with reference numbers of CXSS2400109 and CXSS2400110.

Insulin degludec is a new generation of long-acting basal insulin analog with a duration of action of up to 42 hours, offering stable blood glucose control and a high safety profile. Currently, insulin degludec is classified as Category B in the National Medical Insurance Drug List (2023 edition). Related clinical studies have demonstrated that the Company's insulin degludec injection is comparable to the original drug, Tresiba®, in terms of efficacy and safety.

In the field of diabetes treatment, the Company is also advancing the development of various products, including insulin degludec and insulin aspart injection, insulin degludec liraglutide injection, ultra-long-acting insulin, liraglutide injection, semaglutide injection and UBT251 injection, etc. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 14 October 2024

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.